Table 1.

Trade name (manufacturer)	Presentations	Age indication	μg HA (IIV4s and RIV4) or virus count (LAIV4) for each vaccine virus (per dose)	Route	Mercury (from thimerosal, if present), μg/0.5 mL
IIV4 (standard-dose, egg-based vaccines^†)
Afluria Quadrivalent (Seqirus)	0.5-mL PFS^§	≥3 yrs^§	15 μg/0.5 mL	IM^¶	—**
	5.0-mL MDV^§	≥6 mos^§ (needle and syringe) 18 through 64 yrs (jet injector)	7.5 μg/0.25 mL 15 μg/0.5 mL	IM^¶	24.5
Fluarix Quadrivalent (GlaxoSmithKline)	0.5-mL PFS	≥6 mos	15 μg/0.5 mL	IM^¶	—
FluLaval Quadrivalent (GlaxoSmithKline)	0.5-mL PFS	≥6 mos	15 μg/0.5 mL	IM^¶	—
Fluzone Quadrivalent (Sanofi Pasteur)	0.5-mL PFS^††	≥6 mos^††	15 μg/0.5 mL	IM^¶	—
	0.5-mL SDV^††	≥6 mos^††	15 μg/0.5 mL	IM^¶	—
	5.0-mL MDV^††	≥6 mos^††	7.5 μg/0.25 mL 15 μg/0.5 mL	IM^¶	25
ccIIV4 (standard-dose, cell culture–based vaccine)
Flucelvax Quadrivalent (Seqirus)	0.5-mL PFS	≥6 mos	15 μg/0.5 mL	IM^¶	—
5.0-mL MDV	≥6 mos	15 μg/0.5 mL	IM^¶	25
HD-IIV4 (high-dose, egg-based vaccine^†)
Fluzone High-Dose Quadrivalent (Sanofi Pasteur)	0.7-mL PFS	≥65 yrs	60 μg/0.7 mL	IM^¶	—
aIIV4 (standard-dose, egg-based vaccine^† with MF59 adjuvant)
Fluad Quadrivalent (Seqirus)	0.5-mL PFS	≥65 yrs	15 μg/0.5 mL	IM^¶	—
RIV4 (recombinant HA vaccine)
Flublok Quadrivalent (Sanofi Pasteur)	0.5-mL PFS	≥18 yrs	45 μg/0.5 mL	IM^¶	—
LAIV4 (egg-based vaccine^†)
FluMist Quadrivalent (AstraZeneca)	0.2-mL prefilled single-use intranasal sprayer	2 through 49 yrs	10^6.5–7.5 fluorescent focus units/0.2 mL	NAS	—

Influenza vaccines — United States, 2022–23 influenza season*

Abbreviations: ACIP = Advisory Committee on Immunization Practices; FDA = Food and Drug Administration; HA = hemagglutinin; IIV4 = inactivated influenza vaccine, quadrivalent; IM = intramuscular; LAIV4 = live attenuated influenza vaccine, quadrivalent; MDV = multidose vial; NAS = intranasal; PFS = prefilled syringe; RIV4 = recombinant influenza vaccine, quadrivalent; SDV = single-dose vial.
*Vaccination providers should consult FDA-approved prescribing information for 2022–23 influenza vaccines for the most complete and updated information, including but not limited to indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states. Availability and characteristics of specific products and presentations might change or differ from what is described in this table and in the text of this report.
^†Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of egg-based IIV4s and LAIV4, ACIP recommends that persons with a history of egg allergy may receive any licensed, recommended influenza vaccine that is otherwise appropriate for their age and health status. Those who report having had reactions to egg involving symptoms other than urticaria (e.g., angioedema or swelling, respiratory distress, lightheadedness, or recurrent emesis) or who required epinephrine or another emergency medical intervention should be vaccinated in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, health departments, and physician offices) supervised by a health care provider who is able to recognize and manage severe allergic reactions, if a vaccine other than ccIIV4 or RIV4 is used.
^§The approved dose volume for Afluria Quadrivalent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for persons aged ≥3 years. However, 0.25-mL prefilled syringes are not expected to be available for the 2022–23 season. For children aged 6 through 35 months, a 0.25-mL dose must be obtained from a multidose vial.
^¶IM-administered influenza vaccines should be given by needle and syringe only, with the exception of the MDV presentation of Afluria Quadrivalent, which may alternatively be given by the PharmaJet Stratis jet injector for persons aged 18 through 64 years only. For adults and older children, the recommended site for intramuscular influenza vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Additional specific guidance regarding site selection and needle length for intramuscular administration is available in the ACIP General Best Practice Guidelines for Immunization, available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.
**Not applicable.
^††Fluzone Quadrivalent is currently approved for ages 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however, 0.25-mL prefilled syringes are not expected to be available for the 2022–23 influenza season. If a prefilled syringe of Fluzone Quadrivalent is used for a child in this age group, the dose volume will be 0.5 mL per dose.

Table 2.

Vaccine type	Contraindications	Precautions
Egg-based IIV4s	• History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine^† or to a previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV)^§	• Moderate or severe acute illness with or without fever • History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine
ccIIV4	• History of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any ccIIV or any component of ccIIV4^§	• Moderate or severe acute illness with or without fever • History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine • History of severe allergic reaction to a previous dose of any other influenza vaccine (i.e., any egg-based IIV, RIV, or LAIV)^¶
RIV4	• History of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any RIV or any component of RIV4^§	• Moderate or severe acute illness with or without fever • History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine • History of severe allergic reaction to a previous dose of any other influenza vaccine (i.e., any egg-based IIV, ccIIV, or LAIV)^¶
LAIV4	• History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine^† or to a previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV)^§ • Concomitant aspirin- or salicylate-containing therapy in children and adolescents^§ • Children aged 2 through 4 years who have received a diagnosis of asthma or whose parents or caregivers report that a health care provider has told them during the preceding 12 months that their child had wheezing or asthma or whose medical record indicates a wheezing episode has occurred during the preceding 12 months • Children and adults who are immunocompromised due to any cause, including but not limited to immunosuppression caused by medications, congenital or acquired immunodeficiency states, HIV infection, anatomic asplenia, or functional asplenia (e.g., due to sickle cell anemia) • Close contacts and caregivers of severely immunosuppressed persons who require a protected environment • Pregnancy • Persons with active communication between the CSF and the oropharynx, nasopharynx, nose, or ear or any other cranial CSF leak • Persons with cochlear implants** • Receipt of influenza antiviral medication within the previous 48 hours for oseltamivir and zanamivir, previous 5 days for peramivir, and previous 17 days for baloxavir^††	• Moderate or severe acute illness with or without fever • History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine • Asthma in persons aged ≥5 years • Other underlying medical conditions that might predispose to complications after wild-type influenza infection (e.g., chronic pulmonary, cardiovascular [except isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders [including diabetes mellitus])

Contraindications and precautions for the use of influenza vaccines — United States, 2022–23 influenza season*

Abbreviations: ACIP = Advisory Committee on Immunization Practices; ccIIV = cell culture–based inactivated influenza vaccine (any valency); ccIIV4 = cell culture–based inactivated influenza vaccine, quadrivalent; CSF = cerebrospinal fluid; FDA = Food and Drug Administration; IIV = inactivated influenza vaccine (any valency); IIV4 = inactivated influenza vaccine, quadrivalent; LAIV = live attenuated influenza vaccine (any valency); LAIV4 = live attenuated influenza vaccine, quadrivalent; RIV = recombinant influenza vaccine (any valency); RIV4 = recombinant influenza vaccine, quadrivalent.
*When a contraindication is present, a vaccine should not be administered. When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction (see ACIP General Best Practice Guidelines for Immunization, available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html). Vaccination providers should check FDA-approved prescribing information for 2022–23 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states.
^†Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of egg-based IIV4s and LAIV4, ACIP recommends that persons with a history of egg allergy may receive any licensed, recommended influenza vaccine that is otherwise appropriate for their age and health status. Those who report having had reactions to egg involving symptoms other than urticaria (e.g., angioedema or swelling, respiratory distress, lightheadedness, or recurrent emesis) or who required epinephrine or another emergency medical intervention should be vaccinated in an inpatient or outpatient medical setting, including but not necessarily limited to hospitals, clinics, health departments, and physician offices, if a vaccine other than ccIIV4 or RIV4 is used. Vaccine administration should be supervised by a health care provider who is able to recognize and manage severe allergic reactions.
^§Labeled contraindication noted in package insert.
^¶If administered, vaccination should occur in a medical setting and should be supervised by a health care provider who can recognize and manage severe allergic reactions. Providers can consider consultation with an allergist in such cases, to assist in identification of the component responsible for the allergic reaction.
**Age-appropriate injectable vaccines are recommended for persons with cochlear implant due to the potential for CSF leak, which might exist for a period after implantation. Providers might consider consultation with a specialist concerning risk for persistent CSF leak if an age-appropriate inactivated or recombinant vaccine cannot be used.
^††Use of LAIV4 in context of influenza antivirals has not been studied; however, interference with activity of LAIV4 is biologically plausible, and this possibility is noted in the package insert for LAIV4. In the absence of data supporting an adequate minimum interval between influenza antiviral use and LAIV4 administration, the intervals provided are based on the half-life of each antiviral. The interval between influenza antiviral receipt and LAIV4 for which interference might potentially occur might be further prolonged in the presence of medical conditions that delay medication clearance (e.g., renal insufficiency). Influenza antivirals might also interfere with LAIV4 if initiated within 2 weeks after vaccination. Persons who receive antivirals during the period starting with the specified time before receipt of LAIV4 through 2 weeks after receipt of LAIV4 should be revaccinated with an age-appropriate IIV or RIV4.

Table 3.

Vaccine (of any valency) associated with previous severe allergic reaction (e.g., anaphylaxis)	Available 2022–23 influenza vaccines
	Egg-based IIV4s and LAIV4	ccIIV4	RIV4
Any egg-based IIV or LAIV	Contraindication^†	Precaution^§	Precaution^§
Any ccIIV	Contraindication^†	Contraindication^†	Precaution^§
Any RIV	Contraindication^†	Precaution^§	Contraindication^†
Unknown influenza vaccine	Allergist consultation recommended

Influenza vaccine contraindications and precautions for persons with a history of severe allergic reaction to a previous dose of an influenza vaccine* — United States, 2022–23 influenza season

Abbreviations: ACIP = Advisory Committee on Immunization Practices; ccIIV = cell culture–based inactivated influenza vaccine (any valency); ccIIV4 = cell culture–based inactivated influenza vaccine, quadrivalent; FDA = Food and Drug Administration; IIV = inactivated influenza vaccine (any valency); IIV4 = inactivated influenza vaccine, quadrivalent; LAIV = live attenuated influenza vaccine (any valency); LAIV4 = live attenuated influenza vaccine, quadrivalent; RIV = recombinant influenza vaccine (any valency); RIV4 = recombinant influenza vaccine, quadrivalent.
*Vaccination providers should check FDA-approved prescribing information for 2022–23 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states.
^†When a contraindication is present, a vaccine should not be administered, consistent with ACIP General Best Practice Guidelines for Immunization (Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices [ACIP]. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html). In addition to the contraindications based on history of severe allergic reaction to influenza vaccines that are noted in the table, each individual influenza vaccine is contraindicated for persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of that vaccine. Vaccine components can be found in package inserts. Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of egg-based IIV4s and LAIV4, ACIP recommends that persons with a history of egg allergy may receive any licensed, recommended influenza vaccine that is otherwise appropriate for their age and health status. Those who report having had reactions to egg involving symptoms other than urticaria (e.g., angioedema or swelling, respiratory distress, lightheadedness, or recurrent emesis) or who required epinephrine or another emergency medical intervention should be vaccinated in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, health departments, and physician offices), if a vaccine other than ccIIV4 or RIV4 is used. Vaccine administration should be supervised by a health care provider who is able to recognize and manage severe allergic reactions.
^§When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction, consistent with ACIP General Best Practice Guidelines for Immunization (Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices [ACIP]. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html). Providers can consider using the following vaccines in these instances; however, vaccination should occur in an inpatient or outpatient medical setting with supervision by a health care provider who is able to recognize and manage severe allergic reactions: 1) for persons with a history of severe allergic reaction (e.g., anaphylaxis) to any egg-based IIV or LAIV of any valency, the provider can consider administering ccIIV4 or RIV4; 2) for persons with a history of severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency, the provider can consider administering RIV4; and 3) for persons with a history of severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, the provider can consider administering ccIIV4. Providers can also consider consulting with an allergist to help determine which vaccine component is responsible for the allergic reaction.

Table 4.

Trade name (Manufacturer)	Dose volume for children aged 6 through 35 mos (μg HA per vaccine virus)
Afluria Quadrivalent (Seqirus)	0.25 mL (7.5 μg)^†
Fluarix Quadrivalent (GlaxoSmithKline)	0.5 mL (15 μg)
Flucelvax Quadrivalent (Seqirus)	0.5 mL (15 μg)
FluLaval Quadrivalent (GlaxoSmithKline)	0.5 mL (15 μg)
Fluzone Quadrivalent (Sanofi Pasteur)	0.5 mL (15 μg)^§

Dose volumes for inactivated influenza vaccines approved for children aged 6 through 35 months* — United States, 2022–23 influenza season

Abbreviation: HA = hemagglutinin.
*For persons aged ≥36 months (≥3 years), the dose volume is 0.5 mL per dose for all inactivated influenza vaccines with the exception of Fluzone High-Dose Quadrivalent (HD-IIV4), which is licensed for persons aged ≥65 years and for which the dose volume is 0.7 mL per dose.
^†The approved dose volume for Afluria Quadrivalent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for persons aged ≥3 years. However, 0.25-mL prefilled syringes are not expected to be available for the 2022–23 season. For children aged 6 through 35 months, a 0.25-mL dose must be obtained from a multidose vial.
^§Per the package insert, Fluzone Quadrivalent is currently approved for children aged 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however, 0.25-mL prefilled syringes are no longer available. If a prefilled syringe of Fluzone Quadrivalent is used for a child in this age group, the dose volume will be 0.5 mL per dose. The 0.5-mL single-dose vials should be accessed for only 1 dose and multidose vials for only 10 doses, regardless of the volume of the doses obtained or any remaining volume in the vial. Any vaccine remaining in a vial after the maximum number of doses has been removed should be discarded.

Box.

• Main influenza vaccine types: • IIV = inactivated influenza vaccine • RIV = recombinant influenza vaccine • LAIV = live attenuated influenza vaccine • Numerals following letter abbreviations indicate valency (the number of influenza virus hemagglutinin [HA] antigens represented in the vaccine): • 4 for quadrivalent vaccines: one A(H1N1), one A(H3N2), and two B viruses (one from each lineage) • 3 for trivalent vaccines: one A(H1N1), one A(H3N2), and one B virus (from one lineage) • All influenza vaccines expected to be available in the United States for the 2022–23 season are quadrivalent vaccines. However, abbreviations for trivalent vaccines (e.g., IIV3) might be used in this report when discussing information specific to trivalent vaccines. • Abbreviations for general vaccine categories (e.g., IIV) might be used when discussing information that is not specific to either trivalent or quadrivalent vaccines. • Prefixes are used when necessary to refer to certain specific IIVs: • a for MF59-adjuvanted inactivated influenza vaccine (e.g., aIIV3 and aIIV4) • cc for cell culture–based inactivated influenza vaccine (e.g., ccIIV3 and ccIIV4) • HD for high-dose inactivated influenza vaccine (e.g., HD-IIV3 and HD-IIV4) • SD for standard-dose inactivated influenza vaccine (e.g. SD-IIV3 and SD-IIV4)

• Main influenza vaccine types:
   • IIV = inactivated influenza vaccine
   • RIV = recombinant influenza vaccine
   • LAIV = live attenuated influenza vaccine
• Numerals following letter abbreviations indicate valency (the number of influenza virus hemagglutinin [HA] antigens represented in the vaccine):
   • 4 for quadrivalent vaccines: one A(H1N1), one A(H3N2), and two B viruses (one from each lineage)
   • 3 for trivalent vaccines: one A(H1N1), one A(H3N2), and one B virus (from one lineage)
• All influenza vaccines expected to be available in the United States for the 2022–23 season are quadrivalent vaccines. However, abbreviations for trivalent vaccines (e.g., IIV3) might be used in this report when discussing information specific to trivalent vaccines.
• Abbreviations for general vaccine categories (e.g., IIV) might be used when discussing information that is not specific to either trivalent or quadrivalent vaccines.
• Prefixes are used when necessary to refer to certain specific IIVs:
   • a for MF59-adjuvanted inactivated influenza vaccine (e.g., aIIV3 and aIIV4)
   • cc for cell culture–based inactivated influenza vaccine (e.g., ccIIV3 and ccIIV4)
   • HD for high-dose inactivated influenza vaccine (e.g., HD-IIV3 and HD-IIV4)
   • SD for standard-dose inactivated influenza vaccine (e.g. SD-IIV3 and SD-IIV4)

Abbreviation conventions for influenza vaccines discussed in this report

Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970–78. Am J Public Health 1986;76:761–5. PMID:3717461 https://doi.org/10.2105/AJPH.76.7.761
Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112:798–811. PMID:7457471 https://doi.org/10.1093/oxfordjournals.aje.a113052
Coleman BL, Fadel SA, Fitzpatrick T, Thomas SM. Risk factors for serious outcomes associated with influenza illness in high- versus low-and middle-income countries: systematic literature review and meta-analysis. Influenza Other Respir Viruses 2018;12:22–9. PMID:29197154 https://doi.org/10.1111/irv.12504
Mullooly JP, Bridges CB, Thompson WW, et al.; Vaccine Safety Datalink Adult Working Group. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2007;25:846–55. PMID:17074423 https://doi.org/10.1016/j.vaccine.2006.09.041
Poehling KA, Edwards KM, Griffin MR, et al. The burden of influenza in young children, 2004–2009. Pediatrics 2013;131:207–16. PMID:23296444 https://doi.org/10.1542/peds.2012-1255
Poehling KA, Edwards KM, Weinberg GA, et al.; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Engl J Med 2006;355:31–40. PMID:16822994 https://doi.org/10.1056/NEJMoa054869
Siston AM, Rasmussen SA, Honein MA, et al.; Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010;303:1517–25. PMID:20407061 https://doi.org/10.1001/jama.2010.479
Fragaszy EB, Warren-Gash C, White PJ, et al.; Flu Watch Group. Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: results from the Flu Watch cohort study. Influenza Other Respir Viruses 2018;12:171–82. PMID:28991409 https://doi.org/10.1111/irv.12506
Van Wormer JJ, King JP, Gajewski A, McLean HQ, Belongia EA. Influenza and workplace productivity loss in working adults. J Occup Environ Med 2017;59:1135–9. PMID:28759481 https://doi.org/10.1097/JOM.0000000000001120
Willis GA, Preen DB, Richmond PC, et al.; WAIVE Study Team. The impact of influenza infection on young children, their family and the health care system. Influenza Other Respir Viruses 2019;13:18–27. PMID:30137663 https://doi.org/10.1111/irv.12604
Fiore AE, Uyeki TM, Broder K, et al.; CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(No. RR-8):1–62. PMID:20689501
CDC. How flu vaccine effectiveness and efficacy are measured: questions and answers. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. https://www.cdc.gov/flu/vaccines-work/effectivenessqa.htm
Rolfes MA, Foppa IM, Garg S, et al. Annual estimates of the burden of seasonal influenza in the United States: a tool for strengthening influenza surveillance and preparedness. Influenza Other Respir Viruses 2018;12:132–7. PMID:29446233 https://doi.org/10.1111/irv.12486
Rolfes MA, Flannery B, Chung JR, et al.; US Influenza Vaccine Effectiveness (Flu VE) Network; Influenza Hospitalization Surveillance Network; Assessment Branch, Immunization Services Division, CDC. Effects of influenza vaccination in the United States during the 2017– 2018 influenza season. Clin Infect Dis 2019;69:1845–53. PMID:30715278 https://doi.org/10.1093/cid/ciz075
CDC. 2020–21 flu season summary FAQ. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/flu/season/faq-flu-season-2020-2021.htm
CDC. Fluview. Weekly influenza surveillance report. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/flu/weekly/index.htm
Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 influenza season. MMWR Recomm Rep 2021;70(No. RR-5):1–28. PMID:34448800 https://doi.org/10.15585/mmwr.rr7005a1
Ahmed F. ACIP handbook for developing evidence-based recommendations, Version 1.2. Atlanta, GA: US Department of Health and Human Services, CDC; 2013.
Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 2015;33:246–51. PMID:24962752 https://doi.org/10.1016/j.vaccine.2014.06.052
Radin JM, Hawksworth AW, Myers CA, Ricketts MN, Hansen EA, Brice GT. Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons 2010–2011 through 2013–2014. Vaccine 2016;34:3907–12. PMID:27265447 https://doi.org/10.1016/j.vaccine.2016.05.034
Ray GT, Lewis N, Klein NP, et al. Intraseason waning of influenza vaccine effectiveness. Clin Infect Dis 2019;68:1623–30. PMID:30204855 https://doi.org/10.1093/cid/ciy770
Powell LN, Bégué RE. Influenza vaccine effectiveness among children for the 2017–2018 season. J Pediatric Infect Dis Soc 2020;9:468–73. PMID:31774120 https://doi.org/10.1093/jpids/piz077
Castilla J, Martínez-Baz I, Martínez-Artola V, et al.; Primary Health Care Sentinel Network; Network for Influenza Surveillance in Hospitals of Navarre. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013;18:20388. PMID:23399423 https://doi.org/10.2807/ese.18.05.20388-en
Kissling E, Valenciano M, Larrauri A, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill 2013;18:20390. PMID:23399425 https://doi.org/10.2807/ese.18.05.20390-en
Ferdinands JM, Fry AM, Reynolds S, et al. Intraseason waning of influenza vaccine protection: evidence from the US Influenza Vaccine Effectiveness Network, 2011–12 through 2014–15. Clin Infect Dis 2017;64:544–50. PMID:28039340
Puig-Barberà J, Mira-Iglesias A, Tortajada-Girbés M, et al.; Valencia Hospital Network for the Study of Influenza and other Respiratory Viruses (VAHNSI, Spain). Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine 2017;35:5799–807. PMID:28941618 https://doi.org/10.1016/j.vaccine.2017.09.035
Kissling E, Nunes B, Robertson C, et al.; I-MOVE case–control study team. I-MOVE multicentre case-control study 2010/11 to 2014/15: is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill 2016;21. PMID:27124420 https://doi.org/10.2807/1560-7917.ES.2016.21.16.30201
Pebody R, Andrews N, McMenamin J, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 2013;18:20389. PMID:23399424 https://doi.org/10.2807/ese.18.05.20389-en
Ng Y, Nandar K, Chua LAV, et al. Evaluating the effectiveness of the influenza vaccine during respiratory outbreaks in Singapore's long term care facilities, 2017. Vaccine 2019;37:3925–31. PMID:31160102 https://doi.org/10.1016/j.vaccine.2019.03.054
Young BE, Mak TM, Ang LW, et al. Influenza vaccine failure in the tropics: a retrospective cohort study of waning effectiveness. Epidemiol Infect 2020;148:e299. PMID:33261680 https://doi.org/10.1017/S0950268820002952
Mira-Iglesias A, López-Labrador FX, García-Rubio J, et al. Influenza vaccine effectiveness and waning effect in hospitalized older adults. Valencia Region, Spain, 2018/2019 season. Int J Environ Res Public Health 2021;18:1129. PMID:33514058 https://doi.org/10.3390/ijerph18031129
Ferdinands JM, Gaglani M, Martin ET, et al. Waning vaccine effectiveness against influenza-associated hospitalizations among adults, 2015–2016 to 2018–2019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network. Clin Infect Dis 2021;73:726–9. PMID:33462610 https://doi.org/10.1093/cid/ciab045
Madhi SA, Cutland CL, Kuwanda L, et al.; Maternal Flu Trial (Matflu) Team. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014;371:918–31. PMID:25184864 https://doi.org/10.1056/NEJMoa1401480
Tapia MD, Sow SO, Tamboura B, et al. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis 2016;16:1026–35. PMID:27261067 https://doi.org/10.1016/S1473-3099(16)30054-8
Steinhoff MC, Katz J, Englund JA, et al. Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infect Dis 2017;17:981–9. PMID:28522338 https://doi.org/10.1016/S1473-3099(17)30252-9
Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555–64. PMID:18799552 https://doi.org/10.1056/NEJMoa0708630
CDC. The flu season. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. https://www.cdc.gov/flu/about/season/flu-season.htm
Young B, Sadarangani S, Jiang L, Wilder-Smith A, Chen MI. Duration of influenza vaccine effectiveness: a systematic review, meta-analysis, and meta-regression of test-negative design case-control studies. J Infect Dis 2018;217:731–41. PMID:29220496 https://doi.org/10.1093/infdis/jix632
Ferdinands JM, Alyanak E, Reed C, Fry AM. Waning of influenza vaccine protection: exploring the trade-offs of changes in vaccination timing among older adults. Clin Infect Dis 2020;70:1550–9. PMID:31257422 https://doi.org/10.1093/cid/ciz452
Advisory Committee on Immunization Practices; CDC. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(No. RR-7):1–45. PMID:22108587
Pearson ML, Bridges CB, Harper SA; Healthcare Infection Control Practices Advisory Committee (HICPAC); Advisory Committee on Immunization Practices (ACIP). Influenza vaccination of healthcare personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(No. RR-2):1–16. PMID:16498385
Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
Afluria Quadrivalent [Package Insert]. Parkville, Victoria, Australia: Seqirus; 2022.
Fluzone Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2022.
Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5–8-year-old children. J Infect Dis 2006;194:1032–9. PMID:16991077 https://doi.org/10.1086/507309
Allison MA, Daley MF, Crane LA, et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003–2004 season. J Pediatr 2006;149:755–62. PMID:17137887 https://doi.org/10.1016/j.jpeds.2006.06.036
Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003–2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 2005;116:153–9. PMID:15995046 https://doi.org/10.1542/peds.2005-0049
Eisenberg KW, Szilagyi PG, Fairbrother G, et al.; New Vaccine Surveillance Network. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003–2004 and 2004–2005 influenza seasons. Pediatrics 2008;122:911–9. PMID:18977968 https://doi.org/10.1542/peds.2007-3304
Eick AA, Uyeki TM, Klimov A, et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med 2011;165:104–11. PMID:20921345 https://doi.org/10.1001/archpediatrics.2010.192
ACOG Committee on Obstetric Practice. ACOG Committee opinion no. 732: influenza vaccination during pregnancy. Obstet Gynecol 2018;131:e109–14. PMID:29578985 https://doi.org/10.1097/AOG.0000000000002588
Heikkinen T, Young J, van Beek E, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 2012;207:177.e1–8. PMID:22939717 https://doi.org/10.1016/j.ajog.2012.07.007
Oppermann M, Fritzsche J, Weber-Schoendorfer C, et al. A(H1N1) v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012;30:4445–52. PMID:22564554 https://doi.org/10.1016/j.vaccine.2012.04.081
Pasternak B, Svanström H, Mølgaard-Nielsen D, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 2012;344:e2794. PMID:22551713 https://doi.org/10.1136/bmj.e2794
Sammon CJ, Snowball J, McGrogan A, de Vries CS. Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. PLoS One 2012;7:e51734. PMID:23341865 https://doi.org/10.1371/journal.pone.0051734
Chambers CD, Johnson D, Xu R, et al.; OTIS Collaborative Research Group. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine 2013;31:5026–32. PMID:24016809 https://doi.org/10.1016/j.vaccine.2013.08.097
Huang WT, Tang FW, Yang SE, Chih YC, Chuang JH. Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan. Vaccine 2014;32:6463–8. PMID:25285884 https://doi.org/10.1016/j.vaccine.2014.09.054
Ma F, Zhang L, Jiang R, et al. Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women. Clin Vaccine Immunol 2014;21:1282–7. PMID:24990911 https://doi.org/10.1128/CVI.00375-14
Chambers CD, Johnson DL, Xu R, et al.; OTIS Collaborative Research Group. Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine 2016;34:4443–9. PMID:27449682 https://doi.org/10.1016/j.vaccine.2016.06.054
McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine 2015;33:2108–17. PMID:25758932 https://doi.org/10.1016/j.vaccine.2015.02.068
Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis 2015;60:e11–9. PMID:25409473 https://doi.org/10.1093/cid/ciu915
Irving SA, Kieke BA, Donahue JG, et al.; Vaccine Safety Datalink. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet Gynecol 2013;121:159–65. PMID:23262941 https://doi.org/10.1097/AOG.0b013e318279f56f
Donahue JG, Kieke BA, King JP, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12. Vaccine 2017;35:5314–22. PMID:28917295 https://doi.org/10.1016/j.vaccine.2017.06.069
Donahue JG, Kieke BA, King JP, et al. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012–13, 2013–14, and 2014–15. Vaccine 2019;37:6673–81. PMID:31540812 https://doi.org/10.1016/j.vaccine.2019.09.035
Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179–86. PMID:12517228 https://doi.org/10.1001/jama.289.2.179
CDC. Past seasons vaccine effectiveness estimates. Atlanta, GA: US Department of Health and Human Services, CDC. https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html#2021
DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014;371:635–45. PMID:25119609 https://doi.org/10.1056/NEJMoa1315727
Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine 2009;28:379–85. PMID:19879222 https://doi.org/10.1016/j.vaccine.2009.10.037
Dunkle LM, Izikson R, Patriarca P, et al.; PSC12 Study Team. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med 2017;376:2427–36. PMID:28636855 https://doi.org/10.1056/NEJMoa1608862
Shay DK, Chillarige Y, Kelman J, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012–2013 and 2013–2014. J Infect Dis 2017;215:510–7. PMID:28329311 https://doi.org/10.1093/infdis/jiw641
Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017–2018. J Infect Dis 2019;220:1255–64. PMID:30561688 https://doi.org/10.1093/infdis/jiy716
Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of influenza vaccines among the United States elderly, 2018–2019. J Infect Dis 2020;222:278–87. PMID:32100009 https://doi.org/10.1093/infdis/jiaa080
Izurieta HS, Lu M, Kelman J, et al. Comparative effectiveness of influenza vaccines among U.S. Medicare beneficiaries ages 65 years and older during the 2019–20 season. Clin Infect Dis 2021;73:e4251–9. https://doi.org/10.1093/cid/ciaa1727
Lu Y, Chillarige Y, Izurieta HS, et al. Effect of age on relative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries aged ≥65 years. J Infect Dis 2019;220:1511–20. PMID:31290553 https://doi.org/10.1093/infdis/jiz360
Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 2015;15:293–300. PMID:25672568 https://doi.org/10.1016/S1473-3099(14)71087-4
Richardson DM, Medvedeva EL, Roberts CB, Linkin DR; CDC Epicenter Program. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis 2015;61:171–6. PMID:25829001 https://doi.org/10.1093/cid/civ261
Young-Xu Y, Van Aalst R, Mahmud SM, et al. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among Veterans Health Administration patients. J Infect Dis 2018;217:1718–27. PMID:29452380 https://doi.org/10.1093/infdis/jiy088
Young-Xu Y, Snider JT, van Aalst R, et al. Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method. Vaccine 2019;37:1484–90. PMID:30745146 https://doi.org/10.1016/j.vaccine.2019.01.063
Young-Xu Y, Thornton Snider J, Mahmud SM, et al. High-dose influenza vaccination and mortality among predominantly male, white, senior veterans, United States, 2012/13 to 2014/15. Euro Surveill 2020;25. PMID:32431290 https://doi.org/10.2807/1560-7917.ES.2020.25.19.1900401
Pelton SI, Divino V, Shah D, et al. Evaluating the relative vaccine effectiveness of adjuvanted trivalent influenza vaccine compared to high-dose trivalent and other egg-based influenza vaccines among older adults in the US during the 2017–2018 influenza season. Vaccines (Basel) 2020;8:446. PMID:32784684 https://doi.org/10.3390/vaccines8030446
van Aalst R, Gravenstein S, Mor V, et al. Comparative effectiveness of high dose versus adjuvanted influenza vaccine: a retrospective cohort study. Vaccine 2020;38:372–9. PMID:31606249 https://doi.org/10.1016/j.vaccine.2019.09.105
Pelton SI, Divino V, Postma MJ, et al. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018–19 influenza season. Vaccine 2021;39:2396–407. PMID:33810903 https://doi.org/10.1016/j.vaccine.2021.03.054
DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine 2015;33:4988–93. PMID:26212007 https://doi.org/10.1016/j.vaccine.2015.07.006
Vardeny O, Kim K, Udell JA, et al.; INVESTED Committees and Investigators. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial. JAMA 2021;325:39–49. PMID:33275134 https://doi.org/10.1001/jama.2020.23649
Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med 2017;5:738–46. PMID:28736045 https://doi.org/10.1016/S2213-2600(17)30235-7
McConeghy KW, Davidson HE, Canaday DH, et al. Cluster-randomized trial of adjuvanted versus nonadjuvanted trivalent influenza vaccine in 823 US nursing homes. Clin Infect Dis 2021;73:e4237–43. PMID:32882710 https://doi.org/10.1093/cid/ciaa1233
Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172–80. PMID:19508159 https://doi.org/10.1086/599790
Frey SE, Reyes MR, Reynales H, et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014;32:5027–34. PMID:25045825 https://doi.org/10.1016/j.vaccine.2014.07.013
Schmader KE, Liu CK, Harrington T, et al. Safety, reactogenicity, and health-related quality of life after trivalent adjuvanted vs trivalent high-dose inactivated influenza vaccines in older adults: a randomized clinical trial. JAMA Netw Open 2021;4:e2031266. PMID:33443580 https://doi.org/10.1001/jamanetworkopen.2020.31266
Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocompromised persons. Hum Vaccin Immunother 2018;14:1311–22. PMID:29485353 https://doi.org/10.1080/21645515.2018.1445446
Rubin LG, Levin MJ, Ljungman P, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:e44–100. PMID:24311479 https://doi.org/10.1093/cid/cit684
CDC. Influenza antiviral medications: summary for clinicians. Atlanta, GA: US Department of Health and Human Services, CDC. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
Woo EJ. Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System. Clin Infect Dis 2015;60:777–80. PMID:25428412 https://doi.org/10.1093/cid/ciu948
Woo EJ, Moro PL, Cano M, Jankosky C. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: reports to the Vaccine Adverse Event Reporting System. Vaccine 2017;35:5618–21. PMID:28886946 https://doi.org/10.1016/j.vaccine.2017.08.047
Woo EJ, Moro PL. Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System. Vaccine 2021;39:1812–7. PMID:33678452 https://doi.org/10.1016/j.vaccine.2021.02.052
Uyeki TM, Zane SB, Bodnar UR, et al.; Alaska/Yukon Territory Respiratory Outbreak Investigation Team. Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory. Clin Infect Dis 2003;36:1095–102. PMID:12715302 https://doi.org/10.1086/374053
Mutsch M, Tavernini M, Marx A, et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis 2005;40:1282–7. PMID:15825030 https://doi.org/10.1086/429243
Ratnam I, Black J, Leder K, et al. Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia. J Clin Virol 2013;57:54–8. PMID:23380660 https://doi.org/10.1016/j.jcv.2013.01.008
Millman AJ, Kornylo Duong K, Lafond K, Green NM, Lippold SA, Jhung MA. Influenza outbreaks among passengers and crew on two cruise ships: a recent account of preparedness and response to an ever-present challenge. J Travel Med 2015;22:306–11. PMID:26031322 https://doi.org/10.1111/jtm.12215
Flumist Quadrivalent [Package Insert]. Gaithersburg, MD: MedImmune; 2021.
Rapivab (peramivir for injection) [Package Insert]. Durham, NC: BioCryst; 2017.
Xofluza (baloxavir marboxil) [Package Insert]. San Francisco, CA: Genentech; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf
Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products: general considerations. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2003.
Izikson R, Brune D, Bolduc JS, et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study. Lancet Respir Med 2022;10:392–402. Epub Feb. 21, 2022. PMID:35114141 https://doi.org/10.1016/S2213-2600(21)00557-9
Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007;55:1499–507. PMID:17908055 https://doi.org/10.1111/j.1532-5415.2007.01397.x
Levin MJ, Buchwald UK, Gardner J, et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine 2018;36:179–85. PMID:28830693 https://doi.org/10.1016/j.vaccine.2017.08.029
Frenck RW Jr, Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 2012;19:1296–303. PMID:22739693 https://doi.org/10.1128/CVI.00176-12
Schwarz TF, Flamaing J, Rümke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 2011;29:5195–202. PMID:21619909 https://doi.org/10.1016/j.vaccine.2011.05.031
McNeil SA, Noya F, Dionne M, et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 2007;25:3464–74. PMID:17270320 https://doi.org/10.1016/j.vaccine.2006.12.047
Nakashima K, Aoshima M, Ohfuji S, et al. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial. Hum Vaccin Immunother 2018;14:1923–30. PMID:29561248 https://doi.org/10.1080/21645515.2018.1455476
Song JY, Cheong HJ, Tsai TF, et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine 2015;33:4647–52. PMID:25980426 https://doi.org/10.1016/j.vaccine.2015.05.003
Sukumaran L, McCarthy NL, Kharbanda EO, et al. Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. Obstet Gynecol 2015;126:1069–74. PMID:26444109 https://doi.org/10.1097/AOG.0000000000001066
Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr 2014;168:211–9. PMID:24395025 https://doi.org/10.1001/jamapediatrics.2013.4469
Walter EB, Klein NP, Wodi AP, et al. Fever after influenza, diphtheria-tetanus-acellular pertussis, and pneumococcal vaccinations. Pediatrics 2020;145:e20191909. PMID:32029684 https://doi.org/10.1542/peds.2019-1909
Duffy J, Weintraub E, Hambidge SJ, et al.; Vaccine Safety Datalink. Febrile seizure risk after vaccination in children 6 to 23 months. Pediatrics 2016;138:e20160320. PMID:27273711 https://doi.org/10.1542/peds.2016-0320
Li R, Stewart B, McNeil MM, et al. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013–2014 and 2014–2015 seasons. Pharmacoepidemiol Drug Saf 2016;25:928–34. PMID:27037540 https://doi.org/10.1002/pds.3996
Patterson JL, Carapetian SA, Hageman JR, Kelley KR. Febrile seizures. Pediatr Ann 2013;42:249–54. PMID:24295158 https://doi.org/10.3928/00904481-20131122-09
Nolan T, Bernstein DI, Block SL, et al.; LAIV Study Group. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 2008;121:508–16. PMID:18310199 https://doi.org/10.1542/peds.2007-1064
Lum LC, Borja-Tabora CF, Breiman RF, et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2010;28:1566–74. PMID:20003918 https://doi.org/10.1016/j.vaccine.2009.11.054
Shingrix [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline; 2017.
Fluad Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2022.
Heplisav-B [Package Insert]. Emeryville, CA: Dynavax; 2017.
Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis 2017;216:1352–61. PMID:29029224 https://doi.org/10.1093/infdis/jix481
Fluarix Quadrivalent [Package Insert]. Dresden, Germany: GlaxoSmithKline; 2022.
FluLaval Quadrivalent [Package Insert]. Quebec City, QC, Canada: ID Biomedical Corporation of Quebec; 2022.
Flucelvax Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2022.
Fluzone High-Dose Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2022.
Flublok Quadrivalent [Package Insert]. Meriden, CT: Protein Sciences; 2022.
Food and Drug Administration. Clinical review: Flucelvax Quadrivalent. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016.
Food and Drug Administration. Clinical review: Flucelvax Quadrivalent. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; March 2021.
Food and Drug Administration. Clinical review: Flucelvax Quadrivalent. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; October 2021.

CME / ABIM MOC / CE

Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season

Authors: Lisa A. Grohskopf, MD; Lenee H. Blanton, MPH; Jill M. Ferdinands, PhD; Jessie R. Chung, MPH; Karen R. Broder, MD; H. Keipp Talbot, MD; Rebecca L. Morgan, PhD; Alicia M. Fry, MD
CME / ABIM MOC / CE Released: 12/5/2022
Valid for credit through: 12/5/2023, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 2.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 2.50 ABIM MOC points

Nurses - 2.50 ANCC Contact Hour(s) (2.5 contact hours are in the area of pharmacology)

Pharmacists - 2.50 Knowledge-based ACPE (0.250 CEUs)

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for public health officials, internists, family medicine clinicians, pediatricians, infectious disease clinicians, pulmonologists, nurses, pharmacists, and other clinicians caring for patients in whom seasonal influenza vaccination may be indicated.

The goal of this activity is for learners to be better able to describe the recommendations of the Advisory Committee on Immunization Practices, updated from the 2021 to 2022 recommendations, regarding use of seasonal influenza vaccines in the United States during the 2022 to 2023 season, based on a report published in the Morbidity and Mortality Weekly Report.

Upon completion of this activity, participants will:

Assess changes in the Advisory Committee on Immunization Practices (ACIP) recommendations for 2022-23, updated from the 2021-22 recommendations, regarding the use of seasonal influenza vaccines in the United States during the 2022-23 season, based on a Morbidity and Mortality Weekly Report
Evaluate overall ACIP recommendations regarding use of seasonal influenza vaccines in the United States, based on a Morbidity and Mortality Weekly Report
Describe other ACIP recommendations regarding use of seasonal influenza vaccines in the United States in special populations, and other clinical considerations, based on a Morbidity and Mortality Weekly Report

Faculty

Lisa A. Grohskopf, MD

Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Atlanta, Georgia

Disclosures

Lisa A. Grohskopf, MD, has no relevant financial relationships.

Lenee H. Blanton, MPH

Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Atlanta, Georgia

Disclosures

Lenee H. Blanton, MPH, has no relevant financial relationships.

Jill M. Ferdinands, PhD

Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Atlanta, Georgia

Disclosures

Jill M. Ferdinands, PhD, has no relevant financial relationships.

Jessie R. Chung, MPH

Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Atlanta, Georgia

Disclosures

Jessie R. Chung, MPH, has no relevant financial relationships.

Karen R. Broder, MD

Immunization Safety Office
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, Georgia

Disclosures

Karen R. Broder, MD, has no relevant financial relationships.

H. Keipp Talbot, MD

Division of Infectious Diseases
Vanderbilt University Medical Center
Nashville, Tennessee

Disclosures

H. Keipp Talbot, MD, has no relevant financial relationships.

Rebecca L. Morgan, PhD

Department of Health Research Methods, Evidence, and Impact
McMaster University
Hamilton, Ontario, Canada

Disclosures

Rebecca L. Morgan, PhD, has no relevant financial relationships.

Alicia M. Fry, MD

Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Atlanta, Georgia

Disclosures

Alicia M. Fry, MD, has no relevant financial relationships.

CME Author

Laurie Barclay, MD

Freelance writer and reviewer
Medscape, LLC

Disclosures

Laurie Barclay, MD, has the following relevant financial relationships:
Formerly owned stocks in: AbbVie

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Contact This Provider

For Nurses

Awarded 2.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 2.50 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 2.50 contact hour(s) (0.250 CEUs) (Universal Activity Number: JA0007105-0000-22-346-H06-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

processing....

Influenza Vaccine Composition and Available Vaccines

Influenza Vaccine Composition for the 2022–23 Season

All influenza vaccines licensed in the United States will contain components derived from influenza viruses antigenically similar to those recommended by FDA (https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-march-3-2022-meeting-announcement). All influenza vaccines expected to be available in the United States for the 2022–23 season will be quadrivalent vaccines. For the 2022–23 season, U.S. egg-based influenza vaccines (i.e., vaccines other than ccIIV4 and RIV4) will contain HA derived from

an influenza A/Victoria/2570/2019 (H1N1)pdm09-like virus,
an influenza A/Darwin/9/2021 (H3N2)-like virus,
an influenza B/Austria/1359417/2021 (Victoria lineage)-like virus, and
an influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus.

For the 2022–23 season, U.S. cell culture–based inactivated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from

an influenza A/Wisconsin/588/2019 (H1N1)pdm09-like virus,
an influenza A/Darwin/6/2021 (H3N2)-like virus,
an influenza B/Austria/1359417/2021 (Victoria lineage)-like virus, and
an influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus.

Vaccines Available for the 2022–23 Season

Availability of specific types and brands of licensed seasonal influenza vaccines in the United States is determined by the manufacturers of the vaccines. Information presented concerning vaccines expected to be available and their approved indications and usage reflects current knowledge and is subject to change.

Various influenza vaccines will be available for the 2022–23 season (Table 1). For many vaccine recipients, more than one type or brand of vaccine might be appropriate within approved indications and ACIP recommendations. A licensed influenza vaccine that is appropriate for the recipient's age and health status should be used. Specific age indications for licensed influenza vaccines are summarized (Table 1). Current prescribing information should be consulted for authoritative, up-to-date information. Contraindications and precautions for the different types of influenza vaccines are summarized (Table 2 and Table 3), as are dose volumes (Table 4).

Not all influenza vaccines are likely to be uniformly available in any specific practice setting or geographic locality. Vaccination should not be delayed to obtain a specific product when an appropriate one is available. Within these guidelines and approved indications, ACIP makes no preferential recommendation for the use of any one influenza vaccine over another when more than one licensed, recommended, and age-appropriate vaccine is available, with the exception of selection of influenza vaccines for persons aged ≥65 years (see Older Adults).

Since the publication of the previous season's recommendations, FDA has approved a labeling change for Flucelvax Quadrivalent (see Recent Influenza Vaccine Labeling Changes). Additional new licensures and changes to FDA-approved labeling might occur after publication of this report. As these changes occur and new vaccines become available, they will be reflected in the online version of Table 1, available at https://www.cdc.gov/flu/professionals/acip/2022-2023/acip-table.htm.

Dosage, Administration, Contraindications, and Precautions

Quadrivalent Inactivated Influenza Vaccines (IIV4s). Available Vaccines: As in recent seasons, various inactivated influenza vaccines (IIVs) are expected to be available for 2022–23 (Table 1); all are expected to be quadrivalent (IIV4s). Standard-dose, nonadjuvanted IIV4s are licensed for persons aged as young as 6 months. However, for certain IIV4s, the approved dose volume for children aged 6 through 35 months differs from that for older children and adults (Table 4). Two IIV4s, the MF59-adjuvanted IIV4 (aIIV4) and the high-dose IIV4 (HD-IIV4), are approved for persons aged ≥65 years. Care should be taken to administer the appropriate dose volume of an age-appropriate vaccine to each recipient.

Standard-dose, nonadjuvanted IIV4s contain 15 μg of HA per vaccine virus in a 0.5-mL dose (7.5 μg of HA per vaccine virus in a 0.25-mL dose). For 2022–23, this category is expected to include five different vaccines (Table 1). Four of these are egg-based vaccines, and one is a cell culture–based vaccine. All are approved for persons aged ≥6 months. Egg-based and cell culture–based vaccines differ in the substrate in which reference vaccine viruses supplied to the manufacturer are propagated in quantities sufficient to produce the needed number of doses of vaccine. For the IIV4s Afluria Quadrivalent,^[43] Fluarix Quadrivalent,^[123] FluLaval Quadrivalent,^[124] and Fluzone Quadrivalent,^[44] reference vaccine viruses are propagated in eggs. For Flucelvax Quadrivalent, reference vaccine viruses are propagated in Madin-Darby canine kidney cells instead of eggs.^[125]

Two additional IIV4s that will be available for the 2022–23 season are approved for persons aged ≥65 years. These vaccines are egg based. Quadrivalent high-dose inactivated influenza vaccine (Fluzone High-Dose Quadrivalent; HD-IIV4) contains 60 μg of HA per vaccine virus (240 μg total) in a 0.7-mL dose.^[126] Quadrivalent adjuvanted inactivated influenza vaccine (Fluad Quadrivalent; aIIV4) contains 15 μg of HA per vaccine virus (60 μg total) and MF59 adjuvant.^[120]

Dosage and Administration: Standard-dose nonadjuvanted IIV4s are approved for children aged as young as 6 months. Certain of these IIV4s are approved at different dose volumes for very young children than for older children and adults. Care should be taken to administer an age-appropriate vaccine at the approved dose volume for each needed dose (see Children Aged 6 Through 35 Months: Influenza Vaccine Dose Volumes) (Table 1 and Table 4):

Afluria Quadrivalent: The approved dose volume for children aged 6 through 35 months is 0.25 mL per dose. Persons aged ≥36 months (≥3 years) should receive 0.5 mL per dose.
Fluarix Quadrivalent: The approved dose volume is 0.5 mL per dose for all persons aged ≥6 months.
Flucelvax Quadrivalent: The approved dose volume is 0.5 mL per dose for all persons aged ≥6 months.
FluLaval Quadrivalent: The approved dose volume is 0.5 mL per dose for all persons aged ≥6 months.
Fluzone Quadrivalent: The approved dose volume for children aged 6 through 35 months is either 0.25 mL or 0.5 mL per dose. Persons aged ≥36 months (≥3 years) should receive 0.5 mL per dose.

If prefilled syringes are not available, the appropriate volume can be administered from a single-dose or multidose vial. If a 0.5-mL single-dose vial is used for a 0.25-mL dose for a child aged 6 through 35 months, only half of the vial volume should be administered, and the remaining half should be discarded. Of note, dose volume is distinct from the number of doses. Children in this age group who require 2 doses for 2022–23 need 2 separate doses administered ≥4 weeks apart, regardless of the specific IIV4 used and volume given for each dose (see Children Aged 6 Months Through 8 Years: Number of Influenza Vaccine Doses) (Figure).

For children aged 36 months (3 years) through 17 years and adults aged ≥18 years, the dose volume for IIV4s is 0.5 mL per dose, with the exception of Fluzone High-Dose Quadrivalent (HD-IIV4, licensed for persons aged ≥65 years), for which the correct volume is 0.7 mL per dose. If a smaller vaccine dose (e.g., 0.25 mL) is inadvertently administered to a person aged ≥36 months, the remaining volume needed to make a full dose should be administered during the same vaccination visit or, if measuring the needed remaining volume is a challenge, administering a repeat dose at the full volume is acceptable. If the error is discovered later (after the recipient has left the vaccination setting), a full dose should be administered as soon as the recipient can return. Vaccination with a formulation approved for adult use should be counted as a single dose if inadvertently administered to a child.

IIV4s are administered intramuscularly (IM). For adults and older children, the deltoid muscle is the preferred site. Infants and younger children should be vaccinated in the anterolateral thigh. Additional specific guidance regarding site selection and needle length for IM injection is provided in the ACIP General Best Practice Guidelines for Immunization.^[42]

One IIV4, Afluria Quadrivalent, is licensed for IM injection via the PharmaJet Stratis jet injector for persons aged 18 through 64 years.^[43] Persons in this age group may receive Afluria Quadrivalent via either needle and syringe or this specific jet injection device. Children aged 6 months through 17 years and adults aged ≥65 years should receive this vaccine by needle and syringe only. No other IIV4s are licensed for administration by jet injector.

Contraindications and Precautions for the use of IIV4s: Manufacturer package inserts and updated CDC and ACIP guidance should be consulted for information on contraindications and precautions for individual influenza vaccines. Each IIV, whether egg-based or cell culture–based, has a labeled contraindication for persons with a history of a severe allergic reaction to any component of that vaccine (Table 2). Although egg is a component of all IIV4s other than ccIIV4, ACIP makes specific recommendations for the use of influenza vaccine for persons with egg allergy (see Persons with a History of Egg Allergy). All egg-based IIV4s are contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) to a previous dose of any influenza vaccine (any egg-based IIV, ccIIV, RIV, or LAIV of any valency). Use of ccIIV4 is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency. A history of severe allergic reaction (e.g., anaphylaxis) to any other influenza vaccine (i.e., any egg-based IIV, RIV, or LAIV of any valency) is a precaution for the use of ccIIV4 (see Persons with Previous Allergic Reactions to Influenza Vaccines) (Table 2 and Table 3). If ccIIV4 is administered in such an instance, vaccination should occur in an inpatient or outpatient medical setting and should be supervised by a health care provider who is able to recognize and manage severe allergic reactions. Providers can also consider consultation with an allergist to help identify the vaccine component responsible for the reaction. Information about vaccine components can be found in the package inserts for each vaccine. Prophylactic use of antiviral agents is an option that can be considered for preventing influenza among persons who cannot receive vaccine, particularly for those who are at higher risk for medical complications attributable to severe influenza.^[91]

Moderate or severe acute illness with or without fever is a general precaution for vaccination.^[42] A history of GBS within 6 weeks after receipt of a previous dose of influenza vaccine is considered a precaution for the use of all influenza vaccines (Table 2).

Quadrivalent Recombinant Influenza Vaccine (RIV4). Available Vaccine: One recombinant influenza vaccine, Flublok Quadrivalent (RIV4), is expected to be available during the 2022–23 influenza season. RIV4 is approved for persons aged ≥18 years. This vaccine contains recombinant HA produced in an insect cell line using genetic sequences from cell-derived influenza viruses and is manufactured without the use of influenza viruses or eggs.^[127]

Dosage and Administration: RIV4 is administered by IM injection via needle and syringe. A 0.5-mL dose contains 45 μg of HA derived from each vaccine virus (180 μg total).

Contraindications and Precautions for the Use of RIV4: RIV4 is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) to a previous dose of any RIV of any valency or any component of RIV4. A history of a severe allergic reaction (e.g., anaphylaxis) to any other influenza vaccine (i.e., any egg-based IIV, ccIIV, or LAIV of any valency) is a precaution for the use of RIV4. If RIV4 is administered in such an instance, vaccination should occur in an inpatient or outpatient medical setting and should be supervised by a health care provider who is able to recognize and manage severe allergic reactions. Providers can also consider consulting with an allergist to help identify the vaccine component responsible for the reaction. Moderate or severe acute illness with or without fever is a general precaution for vaccination.^[42] A history of GBS within 6 weeks after receipt of a previous dose of influenza vaccine is considered a precaution for the use of all influenza vaccines (Table 2). RIV4 is not licensed for children aged <18 years.

Quadrivalent Live Attenuated Influenza Vaccine (LAIV4). Available Vaccine: One live attenuated influenza vaccine, FluMist Quadrivalent (LAIV4), is expected to be available during the 2022–23 influenza season. LAIV4 is approved for persons aged 2 through 49 years. LAIV4 contains live attenuated influenza viruses that are propagated in eggs. These viruses are cold adapted (so that they replicate efficiently at 25°C) and temperature sensitive (so that their replication is restricted at higher temperatures, 39°C for influenza A viruses and 37°C for influenza B viruses). These viruses replicate in the nasopharynx, which is necessary to promote an immune response.^[99] No preference is expressed for LAIV4 versus other influenza vaccines used within specified indications.

Dosage and Administration: LAIV4 is administered intranasally using the supplied prefilled, single-use sprayer containing 0.2 mL of vaccine. Approximately 0.1 mL (i.e., half of the total sprayer contents) is sprayed into the first nostril while the recipient is in the upright position. An attached dose-divider clip is removed from the sprayer to permit administration of the second half of the dose into the other nostril. If the recipient sneezes immediately after administration, the dose should not be repeated. However, if nasal congestion is present that might impede delivery of the vaccine to the nasopharyngeal mucosa, deferral of administration should be considered until resolution of the illness, or another appropriate vaccine should be administered instead. Each total dose of 0.2 mL contains 10^6.5–7.5 fluorescent focus units of each vaccine virus.^[99]

Contraindications and Precautions for the use of LAIV4: Conditions considered by ACIP to be contraindications and precautions for the use of LAIV4 are summarized (Table 2). These include two labeled contraindications that appear in the package insert^[99] and other conditions for which there is uncertain but biologically plausible potential risk associated with live viruses or limited data for use of LAIV.

Contraindications to use of LAIV4 include the following:

Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or to a previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency; a labeled contraindication noted in the package insert). However, ACIP makes an exception for allergy to egg (see Persons with a History of Egg Allergy).
Children and adolescents receiving concomitant aspirin- or salicylate-containing medications, because of the potential risk for Reye syndrome (a labeled contraindication noted in the package insert).
Children aged 2 through 4 years who have received a diagnosis of asthma or whose parents or caregivers report that a health care provider has told them during the preceding 12 months that their child had wheezing or asthma or whose medical record indicates a wheezing episode has occurred during the preceding 12 months.
Children and adults who are immunocompromised due to any cause, including but not limited to immunosuppression caused by medications, congenital or acquired immunodeficiency states, HIV infection, anatomic asplenia, or functional asplenia (such as that due to sickle cell anemia).
Close contacts and caregivers of severely immunosuppressed persons who require a protected environment.
Pregnancy.
Persons with active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, or ear or any other cranial CSF leak.
Persons with cochlear implants, because of the potential for CSF leak that might exist for a period after implantation (providers might consider consultation with a specialist concerning the risk for persistent CSF leak if an age-appropriate inactivated or recombinant vaccine cannot be used).
Receipt of influenza antiviral medication within the previous 48 hours for oseltamivir and zanamivir, previous 5 days for peramivir, and previous 17 days for baloxavir. The interval between influenza antiviral receipt and LAIV4 during which interference might potentially occur might be further prolonged in the presence of medical conditions that delay medication clearance (e.g., renal insufficiency).

Precautions for use of LAIV4 include the following:

Moderate or severe acute illness with or without fever.
History of GBS within 6 weeks after receipt of any influenza vaccine.
Asthma in persons aged ≥5 years.
Other underlying medical condition (other than those listed under contraindications) that might predispose to complications after wild-type influenza virus infection (e.g., chronic pulmonary, cardiovascular [except isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders [including diabetes mellitus]).

Recent Influenza Vaccine Labeling Changes

Flucelvax Quadrivalent. Since the publication of the 2021–22 ACIP influenza vaccine recommendations, a labeling change for Flucelvax Quadrivalent (ccIIV4) has occurred. Flucelvax Quadrivalent was initially approved in 2016 for persons aged ≥4 years. Approval for persons aged ≥18 years was based on a randomized immunogenicity and safety trial that compared Flucelvax Quadrivalent with the previously approved trivalent formulation of Flucelvax (ccIIV3), which had previously been licensed for persons aged ≥18 years on the basis of data from a randomized clinical efficacy trial. Approval for children aged 4 through 17 years also was based on immunogenicity and safety data compared with ccIIV3, with a postmarketing requirement to conduct a clinical efficacy study.^[128] In March 2021, FDA approved Flucelvax Quadrivalent for persons aged ≥2 years on the basis of a randomized clinical efficacy trial conducted among 4,514 children aged ≥2 to <18 years over three influenza seasons (Southern Hemisphere 2017 and Northern Hemisphere 2017–18 and 2018–19).^[129]

Subsequently, in October 2021, FDA approved Flucelvax Quadrivalent for persons aged ≥6 months. Approval was based on a randomized immunogenicity and safety study conducted among 2,402 children aged 6 through 47 months (of whom 894 were aged 6 through 23 months). Children were randomized in a 2:1 ratio to receive either Flucelvax Quadrivalent (0.5 mL/dose containing 15 μg HA per virus for all ages) or a licensed comparator egg-based IIV4 (0.25 mL/dose containing 7.5 μg HA per virus for those aged 6 through 35 months and 0.5 mL/dose containing 15 μg HA per virus for those aged 36 through 47 months).^[130] Flucelvax Quadrivalent met prespecified immunogenicity criteria for all four viruses. No new safety signals were noted, and prevalence of solicited injection site and systemic reactions was similar between the two groups.

« Back

Page 5 of 7

Storage and Handling of Influenza Vaccines

Earn Credit CME / ABIM MOC / CE Information

Abstract and Introduction
Methods
Primary Changes and Updates
Recommendations for the use of Influenza Vaccines, 2022–23
Influenza Vaccine Composition and Available Vaccines
Storage and Handling of Influenza Vaccines
Additional Sources of Information Regarding Influenza and Influenza Vaccines

References

Table 1.

Table 2.

Table 3.

Table 4.

Box.

CME / ABIM MOC / CE

Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Faculty

Lisa A. Grohskopf, MD

Lenee H. Blanton, MPH

Jill M. Ferdinands, PhD

Jessie R. Chung, MPH

Karen R. Broder, MD

H. Keipp Talbot, MD

Rebecca L. Morgan, PhD

Alicia M. Fry, MD

CME Author

Laurie Barclay, MD

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season: Influenza Vaccine Composition and Available Vaccines

Influenza Vaccine Composition and Available Vaccines

Influenza Vaccine Composition for the 2022–23 Season

Vaccines Available for the 2022–23 Season

Dosage, Administration, Contraindications, and Precautions

Recent Influenza Vaccine Labeling Changes

Table of Contents

Table 1.

Table 2.

Table 3.

Table 4.

Box.

References

Faculty and Disclosures

Faculty

Lisa A. Grohskopf, MD

Lenee H. Blanton, MPH

Jill M. Ferdinands, PhD

Jessie R. Chung, MPH

Karen R. Broder, MD

H. Keipp Talbot, MD

Rebecca L. Morgan, PhD

Alicia M. Fry, MD

CME Author

Laurie Barclay, MD

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

CME / ABIM MOC / CE

Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Faculty

Lisa A. Grohskopf, MD

Lenee H. Blanton, MPH

Jill M. Ferdinands, PhD

Jessie R. Chung, MPH

Karen R. Broder, MD

H. Keipp Talbot, MD

Rebecca L. Morgan, PhD

Alicia M. Fry, MD

CME Author

Laurie Barclay, MD

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season: Influenza Vaccine Composition and Available Vaccines

Influenza Vaccine Composition and Available Vaccines

Influenza Vaccine Composition for the 2022–23 Season

Vaccines Available for the 2022–23 Season

Dosage, Administration, Contraindications, and Precautions

Recent Influenza Vaccine Labeling Changes

Table of Contents